Abstract:Background Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder cancer treatment but responses vary with patients, for reasons that are still not very clear. Interferon-α (IFN-α) is also used as a therapeutic agent for bladder cancer treatment but the response rate is low. It was found that IFN-α could enhance the cytotoxic effect of MEK inhibition. However, the potential mechanisms of that are still unclear. Understanding of the cross-talk between the IFN-α and MEK/ERK pathway will help enhance the efficacy of IFN-α or MEK inhibitors on bladder cancer. Methods Immunoprecipitation and pull-down assay were used to reveal the formation of signaling complex. The protein expressions were detected by western blot and immunohistochemistry. The cAMP level, Phosphodiesterase 4D (PDE4D) activity and Prostaglandin E 2 (PGE 2 ) concentration in cells, serum and tissues were detected by enzyme-linked immunosorbent assay. The role of PDE4D in bladder tumorigenesis in vivo was examined by the xenograft model. Tissue microarray chips were used to investigate the prognostic roles of PDE4D and tumor progression locus 2 (TPL2) in bladder cancer patients. Results IFN-α down-regulated the cyclooxygenase-2 (COX-2) expression in bladder cancer cells through the inhibition of TPL2/NF-κB pathway; IFN-α also inhibited COX-2 expression by suppressing cAMP signaling through TPL2-ERK mediated PDE4D activity. Reduction of the intracellular cAMP level by PDE4D potentiated the antitumor effect of IFN-α against bladder cancer in vitro and in vivo. Further analysis of clinical samples indicated that low PDE4D expression and high level of TPL2 phosphorylation were correlated to the development and poor prognosis in bladder cancer patients. Conclusions Our data reveal that IFN-α can exert its antitumor effect through a non-canonical JAK-STAT pathway in the bladder cancer cells with low activity of IFN pathway, and the TPL2 inhibition is another function of IFN-α in the context of bladder cancer therapy. The antitumor effects of IFN-α and MEK inhibition also depend on the PDE4D-mediated cAMP level in bladder cancer cells. Suppression of the TPL2 phosphorylation and intracellular cAMP level may be possible therapeutic strategies for enhancing the effectiveness of IFN-α and MEK inhibitors in bladder cancer treatment.

TP53INP2 Modulates Epithelial-to-Mesenchymal Transition via the GSK-3β/β-Catenin/Snail1 Pathway in Bladder Cancer Cells

TP53INP2 Modulates the Malignant Progression of Colorectal Cancer by Reducing the Inactive Form of Β-Catenin.

CIP2A Mediates Fibronectin-Induced Bladder Cancer Cell Proliferation by Stabilizing Β-Catenin

TP53AIP1 induce autophagy via the AKT/mTOR signaling pathway in the breast cancer cells

TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics study

A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer

TP53INP2-related Basal Autophagy is Involved in the Growth and Malignant Progression in Human Liposarcoma Cells.

Α-E-catenin (CTNNA1) Inhibits Cell Proliferation, Invasion and EMT of Bladder Cancer.

TP53INP2 Contributes to Autophagosome Formation by Promoting LC3-ATG7 Interaction.

Long Noncoding RNA XIST Participates in Bladder Cancer by Downregulating P53 Via Binding to TET1

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition

TP53INP1 inhibits hypoxia-induced vasculogenic mimicry formation via the ROS/snail signalling axis in breast cancer.

GINS2 regulates the proliferation and apoptosis of colon cancer cells through PTP4A1

A positive feedback loop between TAZ and miR-942-3p modulates proliferation, angiogenesis, epithelial-mesenchymal transition process, glycometabolism and ROS homeostasis in human bladder cancer

Down-regulation of the ErbB3 Binding Protein 1 in Human Bladder Cancer Promotes Tumor Progression and Cell Proliferation

G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC‐I Via PI3K/Akt Activation in Bladder Cancer

Loss of PPM1A Expression Enhances Invasion and the Epithelial-to-mesenchymal Transition in Bladder Cancer by Activating the TGF-β/Smad Signaling Pathway

Epitulipinolide Diepoxide Induces Apoptosis in Bladder Cancer Cells by Inhibiting the ERK/MAPK Signaling Pathway and Promoting Autophagy

A Long Noncoding RNA GTF2IRD2P1 Suppresses Cell Proliferation in Bladder Cancer by Inhibiting the Wnt/β‑catenin Signaling Pathway

PPP3CB Inhibits Cell Proliferation and the Warburg Effect in Bladder Cancer by Blocking PDHK1

Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D